{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-25-000017","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2025-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.516390+00:00","generated_at":"2026-05-27T22:01:16.380675+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan","bullets":["Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.","Krys Corbett appointed Chief Business Officer; most recently led portfolio strategy at Lyell Immunopharma.","Daryl Gaugler transitions from COO to EVP Commercial Operations; compensation and agreement unchanged.","Board adopted amended inducement plan adding 785,000 shares (total 2,310,000) and extending term to Jan 2035.","Company cites '5x30' strategy to grow commercial base and advance pipeline toward innovative biopharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-25-000017","json":"https://secwatch.observer/filing/0001396814-25-000017.json","markdown":"https://secwatch.observer/filing/0001396814-25-000017.md","text":"https://secwatch.observer/filing/0001396814-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/pcrx-20250116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T22:01:16.380675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f4c73f6ad","claim":"Brendan Teehan was appointed as Chief Commercial Officer at Pacira BioSciences, Inc..","evidence_excerpt":"On January 16, 2025, Brendan Teehan was appointed Chief Commercial Officer of Pacira BioSciences, Inc. (the “Company”), effective January 21, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}]},{"claim_id":"ac2e74c389","claim":"Daryl Gaugler was named as Executive Vice President, Commercial Operations at Pacira BioSciences, Inc..","evidence_excerpt":"On January 16, 2025, Daryl Gaugler was named Executive Vice President, Commercial Operations, instead of his former title as Chief Operating Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000017/0001396814-25-000017-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Executive Vice President, Commercial Operations"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}